Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease

Shiffman D, Slawsky K, Fusfeld L, Devlin JJ, Goss TF

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1016/j.clinthera.2012.04.004

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Aspirin /therapeutic use; Cardiovascular Diseases /prevention & control; Cost-Benefit Analysis; Female; Genetic Testing /economics; Humans; Male; Middle Aged; Primary Prevention

AccessionNumber
22012023671

Date bibliographic record published
03/01/2013